Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes

Clinical Endocrinology

Volumn 62, Issue 1, 2005, Pages 51-55

  Forbes, Shareen ^a,b   Moonan, May ^a   Robinson, Stephen ^a   Anyaoku, Victor ^a   Patterson, Michael ^a   Murphy, Kevin G ^a   Ghatei, Mohammed A ^a   Bloom, Stephen R ^a   Johnston, Desmond G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

ADULT; AREA UNDER CURVE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PREGNANCY; PROTEIN PRECURSORS; SECRETORY RATE;

EID: 12944314998     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02172.x     Document Type: Article

References (34)

1. Ferrannini, E. (1998) Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocrine Reviews, 19, 477-490.
2. Ozaki, K., Okubo, M., Mori, H., Mito, K., Kara, H. & Kohno, N. (2002) Decreased insulin secretion and dyslipidemia coexist in subjects with impaired fasting glucose. Diabetes Research in Clinical Practice, 55, 159-164.
3. WHO (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. WHO, Geneva.
4. O'Sullivan, J.B. (1982) Body weight and subsequent diabetes mellitus. Journal of the American Medical Association, 248, 949-952.
5. Robinson, S. & Johnston, D.G. (1995) Advantage of diabetes? Nature, 375, 640.
6. Dornhorst, A., Bailey, P.C., Anyaoku, V., Elkeles, R.S., Johnston, D.G. & Beard, R.W (1990) Abnormalities of glucose tolerance following gestational diabetes. Quarterly Journal of Medicine, 77, 1219-1228.
7. Dornhorst, A., Chan, S.P., Gelding, S.V., et al. (1992) Ethnic differences in insulin secretion in women at risk of future diabetes. Diabetic Medicine, 9, 258-262.
8. Dornhorst, A., Edwards, S.G., Nicholls, J.S., et al. (1991) A defect in insulin release in women at risk of future non-insulin-dependent diabetes. Clinical Science, 81, 195-199.
9. Kautzky Willer, A., Prager, R., Waldhausl, W., et al. (1997) Pronounced insulin resistance and inadequate β-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care, 20, 1717-1723.
10. Edwards, C.M.,Todd, J.F., Mahmoudi, M., et al. (1999) Glucagonlike peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes, 48, 86-93.
11. Kreymann, B., Williams, G., Ghatei, M.A. & Bloom, S.R. (1987) Glucagon-like peptide-1, 7-36: a physiological incretin in man. Lancet, 2, 1300-1304.
12. Larsson, H., Holst, J.J. & Ahren, B. (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiologica Scandinavia, 160, 413-422.
13. Nauck, M.A., Sauerwald, A., Ritzel, R., Holst, J.J. & Schmiegel, W. (1998) Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care, 21, 1925-1931.
14. Zander, M., Madsbad, S., Madsen, J.L. & Holst, J.J. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel group study. Lancet, 359, 824-830.
15. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S. & Holst, J.J. (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50, 609-613.
16. Humphriss, D.B., Stewart, M.W., Berrish, T.S., et al. (1997) Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia, 40, 1185-1190.
17. Nyholm, B., Walker, M., Gravholt, C.H., et al. (1999) Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia, 42, 1314-1323.
18. Rask, E., Olsson, T., Soderberg, S., et al (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care, 24, 1640-1645.
19. Matsuda, M. & DeFronzo, R.A. (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 22, 1462-1470.
20. Phillips, D.I., Clark, P.M., Hales, C.N. & Osmond, C. (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Medicine, 11, 286-292.
21. Todd, J.F., Edwards, C.M., Ghatei, M.A., Mather, H.M. & Bloom, S.R. (1998) Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clinical Science, 95, 325-329.
22. Freinkel, N., Metzger, B.E., Phelps, R.L., et al. (1986) Gestational diabetes mellitus: a syndrome with phenotypic and genotypic heterogeneity. Hormone Metabolism Research, 18, 427-430.
23. Mitrakou, A., Kelley, D., Mokan, M., et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. New England Journal of Medicine, 326, 22-29.
24. Jolly, M.A.R., Godsland, I., Horvoka, R., Anyaoku, V., Johnston, D. & Robinson, S. (1999) A mechanism for insulin resistance in pregnancy? A study of insulin kinetics. Diabetologia, 42, A597.
25. Mersebach, H., Svendsen, O.L., Holst, J.J., Astrup, A. & Feldt-Rasmussen, U. (2003) Comparisons of leptin, incretins and body composition in obese and lean patients with hypopituitarism and healthy individuals. Clinical Endocrinology, 58, 65-71.
26. Ranganath, L., Norris, F., Morgan, L., Wright, J. & Marks, V. (1999) Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36) amide secretion by circulating non-esterified fatty acids. Clinical Science, 96, 335-342.
27. Deacon, C.F., Johnsen, A.H. & Holst, J.J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism, 80, 952-957.
28. Vilsboll, T., Agerso, H., Krarup, T. & Holst, J.J. (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Journal of Clinical Endocrinology and Metabolism, 88, 220-224.
29. Ryan, E.A., Imes, S., Liu, D., et al. (1995) Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes, 44, 506-512.
30. Perfetti, R. & Merkel, P. (2000) Glucagon-like peptide-1: a major regulator of pancreatic β-cell function. European Journal of Endocrinology, 143, 717-725.
31. Vaag, A.A., Holst, J.J., Volund, A. & Beck Nielsen, H.B. (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. European Journal of Endocrinology, 135, 425-432.
32. Bryer-Ash, M., Cheung, A. & Pederson, R.A. (1994) Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats. Regulatory Peptides, 51, 101-109.
33. Sirinek, K., Pace, W.G., Crockett, S.E., O'Dorisio, T.M., Mazzaferri, E.L. & Cataland, S. (1978) Insulin induced attenuation of glucose stimulated gastric inhibitory polypeptide secretion. American Journal of Surgery, 135, 151-155.
34. O'Sullivan, J.B. (1991) Diabetes mellitus after GDM. Diabetes, 40, 131-135.